French Childhood Cancer Survivor Study

Recruiting

• Conditions: Childhood Solid Tumor

• Registration Number: NCT01620372
• Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary

The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years.

The study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes.

The main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care.

The cohort will be followed for up to 20 years from 2011.

Detailed Description

The main objectives of the FCCSS are to:

* estimate the relationship between doses received (radiotherapy, chemotherapy) at a given organ and risk of second malignancy tumors;

* help identify patients at higher risk;

* compare the mortality occurred among the survivors with the general population;

* investigate the consequences of various intensities of exposure to chemotherapy and/or radiation on health outcomes (such as cardiovascular, cerebrovascular and thyroid diseases, diabetes,...);

* characterize survivors with respect to socioeconomic status and quality of life.

The cohort will be ascertained using:

* the medical records from the treatment centers in order to characterize the childhood cancer, estimate doses of radiotherapy received by all organs and measure the chemotherapy administered;

* the French National Identification Registry and the French Death Registry in order to obtain the vital status and the causes of the deaths for the former patients

* a self-questionnaire that covers the entire future of the survivors (e.g. social status, family network, fertile offspring, access to care, access to bank loans, occupation,...);

* the French National Health Insurance Information System that contains data on all reimbursements for health expenditure including medicinal products as well as outpatient medical and nursing care, prescribed or performed by healthcare professionals.

In an initial cohort, we have already studied the iatrogenic effects of the cancer treatments. We have estimated the doses of ionising radiations delivered by radiotherapy to the target volume and by organs at distance. We found an important role of the radiotherapy and chemotherapy in the risk of a second cancer:

* the cancers occuring after childhood cancer are in excess compared to the general population,

* we studied the relationship between the brain radiation dose and the cerebrovascular mortality,

* there is a high risk of cardiac pathology after anthracyclines administration for a childhood cancer,

* cancer treatments increase the risk of second malignant neoplasms in digestive organs after a very long latency period,

* the risk of thyroid adenoma increased with the radiation dose received by the thyroid during childhood cancer treatment, and plateaued at high doses,

* there is a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received.

Study Timeline

• Study Start: 2011-11
• Study First Submitted: 2012-06-13
• Study First Submitted QC: 2012-06-14
• Study First Posted: 2012-06-15
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-08
• Last Update Posted: 2012-10-10
• Study Completion: 2031-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 18000

Inclusion Criteria

• All types of solid childhood cancer in France
• Age at diagnosis: Below age 19
• Period of diagnosis: between 1st January 1942 and 31st December 1999
• Complete identification (first name, last name, date of birth and place of birth)

Exclusion Criteria

• Leukaemia cases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All health events of interest	by time since diagnosis of solid childhood cancer	* all causes mortality (e.g. cerebrovascular, cardiovascular,...); * all iatrogenic events (e.g. diabetes, thyroid adenomas, cardiac diseases, second malignant solid tumors, secondary leukemia,...)

Trial Locations

Locations (36)

Centre Hospital-Universitaire Hôpital Nord; 🇫🇷 Amiens, France

Centre Hospitalier-Universitaire; 🇫🇷 Angers, France

Centre Hospitalier Universaitaire Hôpital Côte de Nacre; 🇫🇷 Caen, France

Centre Hospitalier Régional Universitaire Hôpital Saint-Jacques; 🇫🇷 Besançon, France

Groupe hospitalier Pellegrin; 🇫🇷 Bordeaux, France

Centre Hospitalier Universitaire Hôpial Hôtel Dieu; 🇫🇷 Clermont Ferrand, France

Centre Hospitalier Universaitaire hôpital d'enfants; 🇫🇷 Dijon, France

Hôpital La Tronche; 🇫🇷 Grenoble, France

Centre Oscar Lambret; 🇫🇷 Lille, France

Institut d'Hématologie et Oncologie Pédiatrique; 🇫🇷 Lyon, France

Hôpital de la mère et de l'enfant; 🇫🇷 Limoges, France

Hôpital Jeanne De Flandre; 🇫🇷 Lille, France

Hôpital d'Enfants de Margency (HEM) Croix Rouge Française; 🇫🇷 Margency, France

Centre Régional de Lutte Contre le Cancer Centre Léon Bérard; 🇫🇷 Lyon, France

AP-HM Hôpital de la Timone; 🇫🇷 Marseille, France

Hôpital Arnaud De Villeneuve; 🇫🇷 Montpellier, France

Institut Curie; 🇫🇷 Paris, France

Centre Hospitalier Universaitaire Hôpital mère-enfant; 🇫🇷 Nantes, France

Centre Antoine Lacassagne; 🇫🇷 Nice, France

GCS Hôpitaux pédiatriques Centre Hospitalier Universitaire Lenval; 🇫🇷 Nice, France

Hôpital Armand Trousseau; 🇫🇷 Paris, France

CHRU de Poitiers La Miletrie; 🇫🇷 Poitiers, France

Institut Jean Godinot; 🇫🇷 Reims, France

Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche; 🇫🇷 Reims, France

Centre Hospitalier Universitaire Hôpital Sud; 🇫🇷 Rennes, France

Institut Claudius Regaud; 🇫🇷 Toulouse, France

Hôpital Charles-Nicolle; 🇫🇷 Rouen, France

Centre Hospitalier Universitaire Hôpital Nord; 🇫🇷 Saint Etienne, France

Centre René Gauducheau de Nantes Atlantique; 🇫🇷 Saint-Herblain, France

Centre Hospitalier de Saintonge; 🇫🇷 Saintes, France

Hôpital Hautepierre; 🇫🇷 Strasbourg, France

Hôpital Clocheville; 🇫🇷 Tours, France

Hôpital Brabois enfants CHU de Nancy; 🇫🇷 Vandoeuvre-les-Nancy, France

Hôpital des Enfants; 🇫🇷 Toulouse, France

Centre Régional de Lutte Contre le Cancer de Lorraine ALEXIS VAUTRIN; 🇫🇷 Vandoeuvre-les-Nancy, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France